Document Detail


New insights on thrombolytic treatment of acute ischemic stroke.
MedLine Citation:
PMID:  11898496     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In 1995, a two-part randomized trial showed the efficacy of intravenous tissue plasminogen activator (tPA) when given within 3 hours of onset of symptoms of acute ischemic stroke. Two subsequent trials were unable to extend the therapeutic window of intravenous tPA beyond 3 hours. A phase IV study performed by experienced stroke centers showed an acceptably low symptomatic intracerebral hemorrhage rate for intravenous tPA of only 3%, whereas a review of the Cleveland area experience showed a disturbingly high rate of symptomatic intracerebral hemorrhage of 15.7%. The Prolyse in Acute Cerebral Thromboembolism (PROACT) II study showed efficacy of intra-arterial pro-urokinase and intravenous heparin over intravenous heparin alone when given within 6 hours of onset of symptoms to patients with thrombotic occlusion of the proximal middle cerebral artery. Additional controlled investigations of intra-arterial thrombolytic therapy are needed. Neuroprotectants in combination with intravenous tPA have yet to show improved efficacy over the use of tPA alone.
Authors:
J F Meschia; T G Brott
Related Documents :
10762516 - Intra-arterial thrombolysis for the treatment of perioperative childhood cardioembolic ...
15197536 - Dilatation induced by 5-ht in the middle meningeal artery of the anaesthetised cat.
3631116 - Role of thrombolysis in peripheral arterial occlusion.
11455286 - An unusual source of massive intra-abdominal hemorrhage during cardio-pulmonary bypass.
14646676 - Addition of cytochalasin d to a biocompatible oil stent coating inhibits intimal hyperp...
7331866 - Complications of coronary angiography.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current neurology and neuroscience reports     Volume:  1     ISSN:  1528-4042     ISO Abbreviation:  Curr Neurol Neurosci Rep     Publication Date:  2001 Jan 
Date Detail:
Created Date:  2002-03-18     Completed Date:  2002-04-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100931790     Medline TA:  Curr Neurol Neurosci Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  19-25     Citation Subset:  IM    
Affiliation:
Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA. meschia.james@mayo.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Animals
Brain Ischemia / complications,  surgery,  therapy*
Fibrinolytic Agents / therapeutic use
Humans
Neuroprotective Agents / therapeutic use
Streptokinase / therapeutic use
Stroke / etiology,  surgery,  therapy*
Thrombolytic Therapy*
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Neuroprotective Agents; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Current status of neuroprotective agents in the treatment of acute ischemic stroke.
Next Document:  The role of neuroimaging in selecting treatments for patients with acute stroke.